2018-07-24 11:05
(2190 d 16:54 ago)

Posting: # 19087
Views: 2,730

 Reference trademark issue [Regulatives / Guidelines]

Dear All,

I prepared protocol for Mesalamine delayed-release tablets 1.2 gm for USFDA submission, i written reference name as Lialda™ (mesalamine) delayed release tablets 1.2 gm with trademark TM and the protocol was approved by EC. But as per COA it is mentioned as Lialda®, there is change in trademark. kindly suggest whether i need to go with ammendment/not.

Vienna, Austria,
2018-07-24 18:57
(2190 d 09:02 ago)

@ rajasekharkakarla
Posting: # 19093
Views: 2,503

 Note to File

Hi Kakarla,

IMHO, no big deal.
stands for an unregistered trademark, as opposed to an registered trademark ®. Will not affect the safety of the subjects in the study. Hence, no substantial amendment (EC and regulatory approval) is required. Maybe just a “Note to File” is enough. If you want to be on the safe side, go for an administrative amendment.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

2018-07-30 15:37
(2184 d 12:21 ago)

@ Helmut
Posting: # 19115
Views: 2,604

 Note to File

Dear Sir,

Thank you for your clarification.

Thanks and Regards,
Kakarla Rajasekhar
UA Flag
 Admin contact
23,113 posts in 4,858 threads, 1,644 registered users;
53 visitors (0 registered, 53 guests [including 14 identified bots]).
Forum time: 03:59 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz